Literature DB >> 15858037

Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels.

Bhavna Chohan1, Dorothy Lang, Manish Sagar, Bette Korber, Ludo Lavreys, Barbra Richardson, Julie Overbaugh.   

Abstract

Designing an effective human immunodeficiency virus type 1 (HIV-1) vaccine will rely on understanding which variants, from among the myriad of circulating HIV-1 strains, are most commonly transmitted and determining whether such variants have an Achilles heel. Here we show that heterosexually acquired subtype A HIV-1 envelopes have signature sequences that include shorter V1-V2 loop sequences and fewer predicted N-linked glycosylation sites relative to the overall population of circulating variants. In contrast, recently transmitted subtype B variants did not, and this was true for cases where the major risk factor was homosexual contact, as well as for cases where it was heterosexual contact. This suggests that selection during HIV-1 transmission may vary depending on the infecting subtype. There was evidence from 23 subtype A-infected women for whom there was longitudinal data that those who were infected with viruses with fewer potential N-linked glycosylation sites in V1-V2 had lower viral set point levels. Thus, our study also suggests that the extent of glycosylation in the infecting virus could impact disease progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858037      PMCID: PMC1091724          DOI: 10.1128/JVI.79.10.6528-6531.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.

Authors:  Cynthia A Derdeyn; Julie M Decker; Frederic Bibollet-Ruche; John L Mokili; Mark Muldoon; Scott A Denham; Marintha L Heil; Francis Kasolo; Rosemary Musonda; Beatrice H Hahn; George M Shaw; Bette T Korber; Susan Allen; Eric Hunter
Journal:  Science       Date:  2004-03-26       Impact factor: 47.728

2.  Gender differences in HIV-1 diversity at time of infection.

Authors:  E M Long; H L Martin; J K Kreiss; S M Rainwater; L Lavreys; D J Jackson; J Rakwar; K Mandaliya; J Overbaugh
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

3.  HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus.

Authors:  E Michelle Long; Stephanie M J Rainwater; Ludo Lavreys; Kishorchandra Mandaliya; Julie Overbaugh
Journal:  AIDS Res Hum Retroviruses       Date:  2002-05-20       Impact factor: 2.205

4.  Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1.

Authors:  M Poss; H L Martin; J K Kreiss; L Granville; B Chohan; P Nyange; K Mandaliya; J Overbaugh
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

5.  Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.

Authors:  Simon D W Frost; Yang Liu; Sergei L Kosakovsky Pond; Colombe Chappey; Terri Wrin; Christos J Petropoulos; Susan J Little; Douglas D Richman
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes.

Authors:  Manish Sagar; Erin Kirkegaard; E Michelle Long; Connie Celum; Susan Buchbinder; Eric S Daar; Julie Overbaugh
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.

Authors:  Ludo Lavreys; Jared M Baeten; Joan K Kreiss; Barbra A Richardson; Bhavna H Chohan; Wisal Hassan; Dana D Panteleeff; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh
Journal:  J Infect Dis       Date:  2004-01-09       Impact factor: 5.226

9.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

Authors:  W A O'Brien; P M Hartigan; D Martin; J Esinhart; A Hill; S Benoit; M Rubin; M S Simberkoff; J D Hamilton
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

10.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

View more
  155 in total

1.  Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Authors:  Ming Li; Jesus F Salazar-Gonzalez; Cynthia A Derdeyn; Lynn Morris; Carolyn Williamson; James E Robinson; Julie M Decker; Yingying Li; Maria G Salazar; Victoria R Polonis; Koleka Mlisana; Salim Abdool Karim; Kunxue Hong; Kelli M Greene; Miroslawa Bilska; Jintao Zhou; Susan Allen; Elwyn Chomba; Joseph Mulenga; Cheswa Vwalika; Feng Gao; Ming Zhang; Bette T M Korber; Eric Hunter; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.

Authors:  Manish Sagar; Xueling Wu; Sandra Lee; Julie Overbaugh
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Role of donor genital tract HIV-1 diversity in the transmission bottleneck.

Authors:  Debrah I Boeras; Peter T Hraber; Mackenzie Hurlston; Tammy Evans-Strickfaden; Tanmoy Bhattacharya; Elena E Giorgi; Joseph Mulenga; Etienne Karita; Bette T Korber; Susan Allen; Clyde E Hart; Cynthia A Derdeyn; Eric Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 4.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

5.  Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.

Authors:  Bing Li; Julie M Decker; Roy W Johnson; Frederic Bibollet-Ruche; Xiping Wei; Joseph Mulenga; Susan Allen; Eric Hunter; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

7.  Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant.

Authors:  Xueling Wu; Adam B Parast; Barbra A Richardson; Ruth Nduati; Grace John-Stewart; Dorothy Mbori-Ngacha; Stephanie M J Rainwater; Julie Overbaugh
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

8.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

9.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Selection of HIV variants with signature genotypic characteristics during heterosexual transmission.

Authors:  Manish Sagar; Oliver Laeyendecker; Sandra Lee; Jordyn Gamiel; Maria J Wawer; Ronald H Gray; David Serwadda; Nelson K Sewankambo; James C Shepherd; Jonathan Toma; Wei Huang; Thomas C Quinn
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.